SLC22A12 and gout: Considering the protective effect of OAT10 dysfunction on gout susceptibility (OR = 0.67) (Higashino et al., 2020), in the context of the potentially simultaneous inhibition of renal URAT1 and OAT10 (Figure 6), it would be interesting to determine whether lesinurad, which had been an approved uricosuric agent that was recently withdrawn from the market unfortunately because of low market penetration, not because of therapeutic issues (Jansen et al., 2022), could have an anti-gout effect stronger than other uricosuric agents that inhibit only URAT1 in clinical situations.